Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Q3 2023 Earnings Presentation
22 slides from Telix Pharmaceuticals's earnings presentation, Oct 18, 2023
Slide 1: Q3 2023 Quarterly Business Update
Q3 2023 Quarterly Positive TLX250-CDx scan (Ph III ZIRCON study) Business Update Telix Pharmaceuticals (ASX:TLX) 18 October 2023
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Q3 2023: Highlights
Q3 2023: Highlights Advancing our industry-leading commercial and clinical theranostic portfolio Commercial Differentiated pipeline Fourth consecutive positive operating diagnostic of first-in-class portfolio therapies cash flow quarter testimony to our ongoing commitment to financial stewardship Co
Slide 4: Q3 2023: Financial metrics
Q3 2023: Financial metrics Consistently strong financial performance Total revenue comparison to previous periods Q3 2023 $133.6M Up 11% on Q2 2023 Net operating Gross Customer Cash Q2 2023 cash inflow margin receipts balance $120.7M $21.4M 63% $130.7M $137.4M Improved Stable COGS1 Improved As at 30
Slide 5: Imaging and technology portfolio
Imaging and technology portfolio • Illuccix® commercial update • TLX250-CDx (renal cancer imaging) • TLX101-CDx (glioma imaging) • Precision-guided surgical tools • Telix AI™
Slide 6: Illuccix: U.S. market share continues to increase
Illuccix: U.S. market share continues to increase Double-digit growth as average daily dose demand continues upward trend • Revenue from U.S. sales of Illuccix up 13% to Revenue from U.S. sales of Illuccix (AU$M) $130.6M (US$85.2M) on the prior quarter 140.0 120.0 130.6 • Average daily dose demand –
Slide 7: PSMA-PET imaging market growth drivers
PSMA-PET imaging market growth drivers Positive outlook for continued growth of Illuccix and the PSMA-PET imaging market Current indications U.S. Total Addressable Market (TAM) 580,000+ scans 1 Initial staging for suspected metastases 1 135,0001 2 Suspected recurrence Current indications: 3 Patient
Slide 8: Supporting patients and physicians throughout the journey
Supporting patients and physicians throughout the journey Guidelines and clinical research highlight potential for expanded utilisation 1) Current indication: Initial 2) Current indication: 3) Current indication: Current staging prior to definitive therapy Suspected recurrence Selection for RLT1 ind
Slide 9: The Illuccix difference
The Illuccix difference Clinical accuracy Recent scientific publications and guidelines illustrate 68Ga-PSMA-11 PET/CT has validated accuracy compared to other PSMA imaging agents h High true positive rates of Established excellence in Accurate interpretation with high detection for regional and dis
Slide 10: The Illuccix difference: wide dosing window
Decay rates of 68Ga and 18F isotopes used in PSMA imaging The Illuccix difference Gallium 68 Decay Chart1, 3 Fluorine 18 Decay Chart2,3 Wide dosing window and flexible (Based on a half life of 67.71 min) (Based on a half life of 109.7 min) Ga-68 mCi mCi mCi mCi mCi F-18 mCi mCi mCi scheduling to mee
Slide 11: Expanded diagnostic and technology portfolio
Expanded diagnostic and technology portfolio Multiple near-term value drivers as we prepare to commercialise new products TLX250-CDx (renal cancer imaging) TLX101-CDx (glioma imaging) • BLA submission progressing as • EAP application filed, expected to planned in 2023 commence in November 2023 • Rol
Slide 12: Clinical Programs
Positive Illuccix® scan Clinical Programs • Clinical program updates 12
Slide 13: Core pipeline: Oncology and rare diseases
Core pipeline: Oncology and rare diseases Prostate PSMA1 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 68Ga Imaging Small molecule TLX591-CDx (68Ga-PSMA-11, Illuccix®) Antibody 177Lu Therapy TLX591 (177Lu rosopatamab tetraxetan) Kidney CAIX2 PHASE 1 PHASE 2 PHASE 3 COMMERCIAL 89Zr Imaging Antibody TLX250-CDx (
Slide 14: Research pipeline: novel targets and technologies
Research pipeline: novel targets and technologies ASSET TARGET ISOTOPE DESCRIPTION STATUS Immuno-oncology 177Lu TLX250 + Merck KGaA DNA Damage Response Inhibitor (DDRi) candidate in Phase Ib study (STARSTRUCK) TLX250 Combo CAIX patients with CAIX-expressing solid tumours in progress Targeted alpha t
Slide 15: Core pipeline highlights
Core pipeline highlights Updates and progress achieved in Q3 2023 CAIX PROGRAM First patient cohort dosed STARLITE-1 & 2 TLX250-CDx OPALESCENCE (INCLUDING RENAL in STARSTRUCK study continuing to enrol EAP1 active in complete, data CANCER) (TLX250 Combo) patients U.S. and E.U. in H1 2024 ProstACT SEL
Slide 16: Financial commentary
Financial commentary • Q3 2023 financial results
Slide 17: Sustainable positive operating cash flow
Sustainable positive operating cash flow Fourth consecutive quarter of net cash inflow from operating activities Cash flow from operating activities ($M) • Cash increased to $137.4M at 30 25.0 20.0 September 2023 (30 June 2023: $131.7M) 21.4 15.0 • Quarterly operating cash flow improved to 10.0 10.8
Slide 18: Sales performance and controlling operating expenditure
Sales performance and controlling operating expenditure Focused investment in priority programs Product-related revenue ($M) and gross margin • Gross margin remains stable from Q1 2023, reflecting percentage stable selling prices and manufacturing processes 140 63% 63% 64% 63% 66% 120 64% 61% • Oper
Slide 19: Continued growth in revenue and adjusted EBITDAR
Continued growth in revenue and adjusted EBITDAR1 Quarterly growth continues Total revenue ($M) 150.0 • Total revenue2 of $133.6M, an 11% improvement on 120.0 133.6 $120.7M in the prior quarter 120.7 90.0 100.1 • Adjusted EBITDAR improved 11% to $50.6M, from 79.0 60.0 $45.6M in the prior quarter, de
Slide 20: Outlook
x ‘e] 2 ad =| O
Slide 21: Recent and upcoming milestones
Recent and upcoming milestones Illuccix® - ProstACT Four key GLOBAL patient BLA submission NDA submission continued recruitment and for kidney cancer for brain cancer catalysts revenue growth data readout imaging imaging and global ProstACT (TLX250-CDx) (TLX101-CDx) rollout SELECT EXPECTED MILESTONE
Slide 22: Contact details
Contact details: Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com 22
Telix Pharmaceuticals — Q3 2023 Earnings Presentation on 6ix